Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in ...
Polymorphous appearance, including pruritus, erythema, edema, vesicles, or necrosis. Usually restricted to areas of skin contact. Contact urticaria, (nonimmunologic) Seconds to minutes Minutes to ...
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
4d
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...
chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries ...
and chronic spontaneous urticaria (CSU). Dupixent for the treatment of COPD has been approved in more than 45 countries worldwide, including the 27 member countries of the EU. About COPD COPD is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback